@article{fb7e0760919747669e3e828369f03cf8,
title = "Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort",
author = "Yazmin Odia and Shih, \{Joanna H.\} and Kreisl, \{Teri N.\} and Fine, \{Howard A.\}",
note = "Bevacizumab is an antiangiogenic agent approved for recurrent glioblastoma due to high response rates. Prior reviews focused on severe or cardiovascular bevacizumab toxicities. We performed a comprehensive review of toxicities experienced among 210 patients enrolled in 3 phase II bevacizumab trials for recurrent malignant gliomas at the National Cancer Institute.",
year = "2014",
month = jan,
day = "11",
doi = "10.1007/s11060-014-1571-6",
language = "American English",
volume = "120",
journal = "Journal of neuro-oncology",
}